Skip to main content

Table 1 Baseline characteristics by group

From: A randomized, double-blind, placebo-controlled, multicenter study assessing the efficacy of magnesium oxide monohydrate in the treatment of nocturnal leg cramps

  MOMH group N = 86 Placebo group N = 87 P Value
Demographics
Gender Female n (%) 65 (75.6) 64 (73.6) 0.862
Age (years) mean (±SD) 57.3 (±10.7) 57.1 (±10.2) 0.955a
Weight (kg) mean (±SD) 74.9 (±13.0) 74.9 (±13.9) 0.995
Height (cm) mean (±SD) 167.4 (±9.6) 167.4 (±9.3) 0.991
BMI (kg/m2) mean (±SD) 26.7 (±4.0) 26.7 (± 4.5) 0.791a
Physiological parameters
Systolic blood pressure (mmHg) mean (±SD) 128.6 (±11.5) 130.0 (±10.3) 0.519a
Diastolic blood pressure (mmHg) mean (±SD) 80.0 (±6.9) 79.0 (±6.2) 0.246a
Heart rate (beats/min) mean (±SD) 71.5 (±6.5) 71.6 (±6.2) 0.934a
Baseline efficacy parameters
NLC frequency (num/week) mean (±SD) 5.4 (±5.0) 6.4 (±8.4) 0.523a
NLC duration (sec/week) mean (±SD) 244.5 (±238.6) 266.5 (±248.9) 0.562a
NLC pain (mean VAS/week) mean (±SD) 6.6 (±1.4) 6.7 (±1.4) 0.584
Sleep quality (mean cumulative score/week) mean (±SD) 13.1 (±3.4) 12.5 (±3.7) 0.327
Quality of life subscales:
- Physical functioning 63.6 (±25.4) 64.8 (±27.5) 0.904a
- Role limitation due to physical health 44.5 (±45.3) 46.6 (±42.7) 0.686a
- Role limitation due to emotional problems 40.7 (±45.0) 40.6 (±43.6) 0.993a
- Vitality 45.9 (±14.5) 45.9 (±12.3) 0.746a
- Mental health 50.1 (±13.6) 49.9 (±11.6) 0.944a
- Social functioning 61.9 (±16.8) 60.1 (±16.3) 0.572a
- Body Pain 47.9 (±17.3) 49.9 (±18.9) 0.640a
- General health 44.9 (±12.1) 45.9 (±9.3) 0.551a
  1. BMI body mass index, MOMH magnesium oxide monohydrate, NLC nocturnal leg cramps, SD standard deviation, VAS visual analogue scale
  2. Note: Variables marked with a were not normally distributed. ANOVA and ANCOVA on ranks were performed for comparisons of these variables